Protocol for the donation of samples by volunteers for laboratory research

ISRCTN ISRCTN13109642
DOI https://doi.org/10.1186/ISRCTN13109642
IRAS number 149078
Secondary identifying numbers DS-10-01, IRAS 149078, 46616
Submission date
02/02/2023
Registration date
03/02/2023
Last edited
18/04/2024
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
This study aims to obtain blood and/or urine, stool, skin, sputum, saliva, mucosal or nasal samples from healthy volunteers and patient volunteers for laboratory research, relating to the causes and treatment of disease, in order to identify markers of disease and drug effect or development of new laboratory methods.

Who can participate?
Men and women 18 years old or over

What does the study involve?
This study will involve ad hoc visits to the Medicines Evaluation Unit. After written informed consent is obtained, participants will be assessed for their eligibility to donate the samples required according to the specific procedure to be undertaken. Participants have one or more of the following samples taken at a single visit: sputum, blood, urine, nasal, stool or skin.

What are the possible benefits and risks of participating?
All sampling procedures are considered safe. There is a small risk of side effects such as bruising, bleeding and infection. This is laboratory research so there is no direct benefit to the participant.

Where is the study run from?
Medicines Evaluation Unit (UK)

When is the study starting and how long is it expected to run for?
November 2009 to December 2030

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Clinical Research Leader

Contact information

Miss Natalie Jackson
Public

MEU
The Langley Building
Southmoor Road
Manchester
M23 9QZ
United Kingdom

Phone +44 (0)1619464065
Email njackson@meu.org.uk
Miss Natalie Jackson
Scientific

MEU
The Langley Building
Southmoor Road
Manchester
M23 9QZ
United Kingdom

Phone +44 (0)1619464065
Email njackson@meu.org.uk
Prof Dave Singh
Principal Investigator

MEU
The Langley Building
Southmoor Road
Manchester
M23 9QZ
United Kingdom

Phone +44 (0)1619464073
Email dsingh@meu.org.uk

Study information

Study designObservational cross sectional study
Primary study designObservational
Secondary study designCross sectional study
Study setting(s)Pharmaceutical testing facility
Study typeDiagnostic
Participant information sheet Not available in web format, please use the contact details to request a participant information sheet
Scientific titleProtocol for the donation of blood, urine, stool, dermatological, sputum and nasal samples by healthy volunteers and patient volunteers for laboratory research
Study objectivesIdentifying markers of disease and developing new assays
Ethics approval(s)Approved 12/04/2010, North West Preston Research Ethics Committee (HRA Centre Manchester, Barlow House, 3rd Floor, 4 Minshull Street, Manchester M1 3DZ, UK; +44 (0)2071048290; preston.rec@hra.nhs.uk), ref: 10/H1016/25
Health condition(s) or problem(s) studiedHealthy volunteers and patient volunteers of all conditions
InterventionParticipants have one or more of the following samples taken at a single visit: sputum, blood, urine, nasal, stool or skin.
Intervention typeOther
Primary outcome measureSputum eosinophil counts in stable state measured using cytology at a single timepoint
Secondary outcome measuresSputum supernatant cytokines including IL-8 and TNF-α in stable state measured using immunoassay at a single timepoint
Overall study start date01/11/2009
Completion date31/12/2030

Eligibility

Participant type(s)Mixed
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsAt least 2000
Key inclusion criteria1. Able to give written informed consent
2. Males and females aged over 18 years
3. Procedure specific criteria
Key exclusion criteria1. History of anaemia or identified by haemocue test at screening or other clinically significant haematological disorders for blood donation
2. Current acute illness
3. Pregnancy or breastfeeding
4. History of Hepatitis B/C or HIV infection or a positive test at screen if required by the specific project
5. Volunteers who have donated to the blood transfusion service in the past 4 months, if applicable (applicable for blood donation or if specified for other procedures as per project-specific exclusion criteria)
6. Suspected use of drugs of abuse or positive drug screen, if required
7. Any contraindications for nasal sampling e.g. history of epistaxis, nasal defects, as assessed by the physician
8. Procedure-specific criteria and contraindications for performing the specific procedure
9. Any reason that the physician deems the subject not suitable to undertake the procedure(s)
Date of first enrolment07/05/2010
Date of final enrolment31/12/2029

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Medicines Evaluation Unit Limited
The Langley Building
Southmoor Road
Wythenshawe
Manchester
M23 9QZ
United Kingdom

Sponsor information

Medicines Evaluation Unit
Research organisation

The Langley Building
Southmoor Road
Manchester
M23 9QZ
England
United Kingdom

Phone +44 (0)161 9464050
Email drogers@meu.org.uk
Website http://www.meu.org.uk/
ROR logo "ROR" https://ror.org/05e497m36

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date01/01/2025
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planPlanned publications in high-impact peer-reviewed journals, the first one in 2025.
IPD sharing planThe datasets generated during and/or analysed during the current study are not expected to be made available due to the exploratory nature of the research and assays.

Editorial Notes

18/04/2024: A study contact confirmed the record required no changes at this time.
02/03/2023: IRAS number added.
03/02/2023: Trial's existence confirmed by the North West Preston Research Ethics Committee.